论文部分内容阅读
新疗法为肾衰竭带来希望盐湖城跨山医疗中心肾移植项目的研究人员称,使用达拉他明(Daratumumab)在世界范围内首次成功治疗“单克隆丙种球蛋白肾病”。在患有这种疾病的患者体内,骨髓中的单克隆浆细胞会产生一种不正常的蛋白质,沉积在肾脏中,引起炎症,从而影响器官的功能。如果不及时治疗,肾脏最终会衰竭。不幸的是,肾脏移植并不能解决这个问题,因为这些异常蛋白的持续存在最终会破坏新的肾脏。移植手术后的免疫系统受损使患者更容易受副作用影响,而患者只能选择“终生透析”。而使用达拉他明可以直接靶向产生异常蛋白的浆细胞克
New Therapy Brings Hope to Kidney Failure Researchers at the Transplantation Center for Salt Mountain Medical Center in Mountain Cross, have reported the first successful worldwide trial of “monoclonal gamma globulin nephropathy” using Daratumumab. In patients with this condition, the monoclonal plasma cells in the bone marrow produce an abnormal protein that deposits in the kidneys and causes inflammation that affects the functioning of the organ. If not treated, the kidneys eventually fail. Unfortunately, kidney transplants do not solve the problem, because the persistence of these abnormal proteins can eventually destroy the new kidneys. Damage to the immune system following transplant surgery makes patients more susceptible to side effects, and patients can only choose “lifelong dialysis ”. The use of daltantamine can directly target abnormal protein-producing plasma cells g